Aignostics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aignostics is a Berlin-based computational pathology company applying AI to histopathology image analysis for drug development and clinical diagnostics; raised €45M+ total including a €37M Series B in 2024;
About
Aignostics is a Berlin-based precision pathology company founded in 2019 as a spinout from Charité – Universitätsmedizin Berlin, one of Europe''s largest university hospitals. The company develops foundation models and AI-powered image analysis tools for computational pathology — applying deep learning to digitized histopathology slides (whole slide images) to detect, classify, and quantify cellular and tissue features at scale. Its technology enables pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories to analyze tissue samples faster, more consistently, and with greater quantitative depth than human pathologists alone.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.